12:00 AM
Feb 14, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hybrid Capture II human papillomavirus: Marketed as an adjunct to the Pap smear for cervical cancer screening

Researchers presented preliminary data from 1,977 patients showing 98 percent sensitivity and 85 percent specificity in disease detection with DIGE's HPV test. By comparison, liquid...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >